New GJA8 variants and phenotypes highlight its critical role in a broad spectrum of eye anomalies.


Journal

Human genetics
ISSN: 1432-1203
Titre abrégé: Hum Genet
Pays: Germany
ID NLM: 7613873

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 22 11 2017
accepted: 09 02 2018
pubmed: 22 2 2018
medline: 31 8 2019
entrez: 22 2 2018
Statut: ppublish

Résumé

GJA8 encodes connexin 50 (Cx50), a transmembrane protein involved in the formation of lens gap junctions. GJA8 mutations have been linked to early onset cataracts in humans and animal models. In mice, missense mutations and homozygous Gja8 deletions lead to smaller lenses and microphthalmia in addition to cataract, suggesting that Gja8 may play a role in both lens development and ocular growth. Following screening of GJA8 in a cohort of 426 individuals with severe congenital eye anomalies, primarily anophthalmia, microphthalmia and coloboma, we identified four known [p.(Thr39Arg), p.(Trp45Leu), p.(Asp51Asn), and p.(Gly94Arg)] and two novel [p.(Phe70Leu) and p.(Val97Gly)] likely pathogenic variants in seven families. Five of these co-segregated with cataracts and microphthalmia, whereas the variant p.(Gly94Arg) was identified in an individual with congenital aphakia, sclerocornea, microphthalmia and coloboma. Four missense variants of unknown or unlikely clinical significance were also identified. Furthermore, the screening of GJA8 structural variants in a subgroup of 188 individuals identified heterozygous 1q21 microdeletions in five families with coloboma and other ocular and/or extraocular findings. However, the exact genotype-phenotype correlation of these structural variants remains to be established. Our data expand the spectrum of GJA8 variants and associated phenotypes, confirming the importance of this gene in early eye development.

Identifiants

pubmed: 29464339
doi: 10.1007/s00439-018-1875-2
pii: 10.1007/s00439-018-1875-2
doi:

Substances chimiques

Connexins 0
Eye Proteins 0
connexin 50 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1042

Subventions

Organisme : Spanish Institute of Health Carlos III
ID : CP12/03256
Organisme : Spanish Ministry of Economy and Competitiveness
ID : SAF2013-46943-R
Organisme : Health Innovation Challenge Fund
ID : HICF-1009-003

Références

Development. 2002 Jan;129(1):167-74
pubmed: 11782410
Science. 2002 Jan 11;295(5553):319-20
pubmed: 11786642
Exp Eye Res. 2001 Dec;73(6):867-76
pubmed: 11846517
Hum Mol Genet. 2002 Mar 1;11(5):507-13
pubmed: 11875045
Curr Biol. 2005 Jan 26;15(2):R64-7
pubmed: 15668160
Genome Res. 2005 Aug;15(8):1034-50
pubmed: 16024819
Mol Vis. 2006 Mar 23;12:190-5
pubmed: 16604058
Development. 2006 May;133(10):2033-40
pubmed: 16611690
Exp Eye Res. 2007 Mar;84(3):513-28
pubmed: 17217947
Am J Hum Genet. 2007 Feb;80(2):232-40
pubmed: 17236129
J Med Genet. 2007 Jul;44(7):e85
pubmed: 17601931
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3937-44
pubmed: 17724170
Mol Vis. 2008 Feb 09;14:323-6
pubmed: 18334946
Mol Vis. 2008 May 07;14:823-8
pubmed: 18470322
Mol Vis. 2008 May 09;14:851-6
pubmed: 18483562
Nature. 2008 Sep 11;455(7210):232-6
pubmed: 18668039
N Engl J Med. 2008 Oct 16;359(16):1685-99
pubmed: 18784092
Nat Genet. 2008 Dec;40(12):1466-71
pubmed: 19029900
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Hum Mutat. 2009 Oct;30(10):1378-86
pubmed: 19708017
Annu Rev Med. 2010;61:437-55
pubmed: 20059347
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Invest Ophthalmol Vis Sci. 2011 Feb 01;52(1):558-64
pubmed: 20574025
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Mol Vis. 2010 Aug 11;16:1585-92
pubmed: 20806042
Hum Mol Genet. 2010 Oct 15;19(R2):R176-87
pubmed: 20807775
Eur J Clin Invest. 2011 Jan;41(1):103-16
pubmed: 20840374
PLoS Comput Biol. 2010 Dec 02;6(12):e1001025
pubmed: 21152010
Am J Physiol Cell Physiol. 2011 May;300(5):C1055-64
pubmed: 21228318
Am J Ophthalmol. 2011 Jun;151(6):1087-1094.e45
pubmed: 21353197
J Biol Chem. 2011 May 13;286(19):16914-28
pubmed: 21454606
Mol Vis. 2011;17:1508-13
pubmed: 21686328
Mol Genet Metab. 2011 Dec;104(4):448-56
pubmed: 22005280
Ophthalmology. 2012 Feb;119(2):362-8
pubmed: 22054996
Hum Mutat. 2012 Mar;33(3):457-66
pubmed: 22213154
Eur J Hum Genet. 2012 Jul;20(7):754-61
pubmed: 22317977
PLoS One. 2012;7(12):e52894
pubmed: 23300808
Invest Ophthalmol Vis Sci. 2013 Feb 07;54(2):1135-43
pubmed: 23349431
Front Pharmacol. 2013 Apr 15;4:43
pubmed: 23596416
Mol Vis. 2013 May 29;19:1141-8
pubmed: 23734083
JAMA Ophthalmol. 2013 Dec;131(12):1517-24
pubmed: 24177921
Invest Ophthalmol Vis Sci. 2013 Nov 19;54(12):7614-22
pubmed: 24204043
Eur J Hum Genet. 2014 Jul;22(7):907-15
pubmed: 24281366
Bioinformatics. 2014 Oct;30(19):2813-5
pubmed: 24907369
Ophthalmology. 2014 Nov;121(11):2124-37.e1-2
pubmed: 25148791
Genes Dev. 2014 Sep 1;28(17):1879-84
pubmed: 25184676
Hum Genomics. 2014 Nov 18;8:19
pubmed: 25403472
Lancet. 2015 Apr 4;385(9975):1305-14
pubmed: 25529582
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2173-82
pubmed: 25698705
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Birth Defects Res C Embryo Today. 2015 Jun;105(2):96-113
pubmed: 26046913
Genet Med. 2016 Apr;18(4):341-9
pubmed: 26066539
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Hum Mutat. 2016 Mar;37(3):235-41
pubmed: 26555599
Hum Mutat. 2016 Apr;37(4):371-84
pubmed: 26694549
Sci Rep. 2016 Feb 25;6:22024
pubmed: 26912477
Am J Med Genet A. 2016 Jul;170(7):1895-8
pubmed: 27103084
Sci Rep. 2016 May 24;6:26551
pubmed: 27216975
BMC Cell Biol. 2016 May 24;17 Suppl 1:17
pubmed: 27228968
Exp Eye Res. 2017 Mar;156:95-102
pubmed: 27334249
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Mol Cytogenet. 2016 Sep 29;9:74
pubmed: 27708714
Hum Genet. 2017 Jan;136(1):119-127
pubmed: 27844144
Sci Rep. 2017 Dec;7(1):53
pubmed: 28246397
Iran J Basic Med Sci. 2017 Mar;20(3):288-293
pubmed: 28392901
Clin Genet. 2018 Jan;93(1):155-159
pubmed: 28455998
PLoS One. 2017 Aug 21;12(8):e0183438
pubmed: 28827829
G3 (Bethesda). 2017 Oct 5;7(10):3257-3268
pubmed: 28839118
Cell. 1997 Dec 12;91(6):833-43
pubmed: 9413992
Curr Eye Res. 1998 Sep;17(9):883-9
pubmed: 9746435
J Cell Biol. 1998 Nov 2;143(3):815-25
pubmed: 9813099

Auteurs

Fabiola Ceroni (F)

Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Oxford, OX3 0BP, UK.

Domingo Aguilera-Garcia (D)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Nicolas Chassaing (N)

Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Toulouse, France.
UMR 1056 Inserm, Université de Toulouse, Toulouse, France.

Dorine Arjanne Bax (DA)

Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Oxford, OX3 0BP, UK.

Fiona Blanco-Kelly (F)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.
Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Institute of Ophthalmology, University College London, London, UK.

Patricia Ramos (P)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Maria Tarilonte (M)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Cristina Villaverde (C)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Luciana Rodrigues Jacy da Silva (LRJ)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Maria Juliana Ballesta-Martínez (MJ)

Medical Genetics Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.

Maria Jose Sanchez-Soler (MJ)

Medical Genetics Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.

Richard James Holt (RJ)

Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Oxford, OX3 0BP, UK.

Lisa Cooper-Charles (L)

West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Jonathan Bruty (J)

West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Yvonne Wallis (Y)

West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Dominic McMullan (D)

West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Jonathan Hoffman (J)

West Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2TG, UK.

David Bunyan (D)

Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK.

Alison Stewart (A)

Sheffield Clinical Genetics Department, Northern General Hospital, Sheffield, UK.

Helen Stewart (H)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Katherine Lachlan (K)

Wessex Clinical Genetics Service, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Human Genetics and Genomic Medicine, Southampton General Hospital, University of Southampton, Southampton, UK.

Alan Fryer (A)

Cheshire and Merseyside Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, UK.

Victoria McKay (V)

Cheshire and Merseyside Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, UK.

Joëlle Roume (J)

Department of Clinical Genetics, Centre de Référence "AnDDI Rares", Poissy Hospital GHU PIFO, Poissy, France.

Pascal Dureau (P)

Fondation Ophtalmologique Adolphe-de-Rothschild, Paris, France.

Anand Saggar (A)

Clinical Genetics Unit, St Georges University of London, London, UK.

Michael Griffiths (M)

West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Patrick Calvas (P)

Service de Génétique Médicale, Hôpital Purpan, CHU Toulouse, Toulouse, France.
UMR 1056 Inserm, Université de Toulouse, Toulouse, France.

Carmen Ayuso (C)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Marta Corton (M)

Genetics Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Centre for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Nicola K Ragge (NK)

Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Oxford, OX3 0BP, UK. nragge@brookes.ac.uk.
West Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2TG, UK. nragge@brookes.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH